1
|
Sato M, Yamazaki J, Goto-Koshino Y, Setoguchi A, Takahashi M, Baba K, Fujino Y, Ohno K, Tsujimoto H. Minimal residual disease in canine lymphoma: An objective marker to assess tumour cell burden in remission. Vet J 2016; 215:38-42. [DOI: 10.1016/j.tvjl.2016.05.012] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2014] [Revised: 05/12/2016] [Accepted: 05/24/2016] [Indexed: 10/21/2022]
|
2
|
Gentilini F, Turba ME, Forni M. Retrospective monitoring of minimal residual disease using hairpin-shaped clone specific primers in B-cell lymphoma affected dogs. Vet Immunol Immunopathol 2013; 153:279-88. [PMID: 23602204 DOI: 10.1016/j.vetimm.2013.03.012] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2012] [Revised: 12/20/2012] [Accepted: 03/22/2013] [Indexed: 10/27/2022]
Abstract
Lymphoma is one of the most common forms of cancer in dogs as it is in humans but, unlike humans, the cure rates in canines are still very low. Despite the fact that high grade B-cell lymphomas are considered to be chemotherapy responsive, almost all treated dogs ultimately relapse and die due to the residual malignant lymphocytes, namely minimal residual disease (MRD). It would be extremely valuable for clinicians to detect, monitor and quantify MRD for risk group stratification, effective treatment intervention and outcome prediction. The PCRs targeting the Ig gene rearrangements constitute one of the most reliable tools to this end. We have recently validated a method which exploits hairpin-shaped primers for quantifying MRD. In the present study, that method is conveniently used for retrospectively monitoring MRD in the peripheral blood of 8 dogs diagnosed with B-cell lymphoma who underwent chemotherapy. All dogs attained complete remission. The median disease-free interval was 254.5 days (range 63-774) while the median survival time was 313.5 days (range 143-817 days). At admission, all dogs, except one which had already been treated with prednisone, had circulating neoplastic cells. All dogs attained complete remission (CR) which was almost always matched with a complete MRD response. The persistence of MRD despite apparent CR indicated a worse prognosis and a short duration of CR. Finally, the relapse is consistently anticipated by the reappearance of MRD in the peripheral blood. The study confirmed the suitability of an MRD monitoring assay as a clinical decision-making tool.
Collapse
Affiliation(s)
- Fabio Gentilini
- Department of Veterinary Medical Sciences, University of Bologna, Ozzano dell'Emilia, Bologna, Italy.
| | | | | |
Collapse
|
3
|
Sato M, Yamazaki J, Goto-Koshino Y, Takahashi M, Fujino Y, Ohno K, Tsujimoto H. Increase in Minimal Residual Disease in Peripheral Blood before Clinical Relapse in Dogs with Lymphoma that Achieved Complete Remission after Chemotherapy. J Vet Intern Med 2011; 25:292-6. [DOI: 10.1111/j.1939-1676.2010.0675.x] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
4
|
Gentilini F, Turba ME, Calzolari C, Cinotti S, Forni M, Zannoni A. Real-time quantitative PCR using hairpin-shaped clone-specific primers for minimal residual disease assessment in an animal model of human non-Hodgkin lymphoma. Mol Cell Probes 2009; 24:6-14. [PMID: 19651205 DOI: 10.1016/j.mcp.2009.07.006] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2009] [Revised: 07/06/2009] [Accepted: 07/28/2009] [Indexed: 11/28/2022]
Abstract
A multitude of molecular techniques for monitoring minimal residual disease in lymphoproliferative disorders have been described to date. Real-Time Quantitative PCR targeting Immunoglobulin Heavy chain patient-specific sequences is increasingly being used for molecular detection of residual neoplastic B-cells using allele-specific oligos. The establishment of individually tailored PCR assays with the extensive use of patient-specific fluorescent-labeled oligos may be cumbersome and expensive. The present study was aimed at evaluating the usefulness of recently described hairpin-shaped allele-specific primers, originally intended for typing single-nucleotide polymorphisms, for the assessment of minimal residual disease using SYBR Green intercalating dye. Three cloned and 2 sequenced clonogenic Ig heavy chain rearranged gene loci, obtained from 5 cases of canine spontaneous B-cell lymphoma, were used as an experimental model. Both standard linear and hairpin-shaped forward and reverse clone-specific primers were evaluated in terms of specificity, sensitivity and PCR efficiency. Hairpin-shaped primers were demonstrated to have achieved accurate results more consistently than the respective linear primers allowing the specific and sensitive quantification of minimal residual disease of lymphoproliferative disorders with fewer validation procedures and more flexibility on the assay design.
Collapse
Affiliation(s)
- Fabio Gentilini
- Veterinary Clinical Department, Alma Mater Studiorum-University of Bologna, Bologna, Italy.
| | | | | | | | | | | |
Collapse
|
5
|
Hagiwara K, Li Y, Kinoshita T, Kunishma S, Ohashi H, Hotta T, Nagai H. Aberrant DNA methylation of the p57KIP2 gene is a sensitive biomarker for detecting minimal residual disease in diffuse large B cell lymphoma. Leuk Res 2009; 34:50-4. [PMID: 19616848 DOI: 10.1016/j.leukres.2009.06.028] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2009] [Revised: 06/22/2009] [Accepted: 06/24/2009] [Indexed: 10/20/2022]
Abstract
The detection of minimal residual disease (MRD) in bone marrow is very important in the clinical management of malignant lymphoma. So far, the assessment of MRD in cases of diffuse large B cell lymphoma (DLBCL) has had some technical limitations, such as requiring patient-specific primers and complicated experimental steps. To resolve these problems, we applied a tumor-specific epigenetic alteration of the p57KIP2 gene as a biomarker for detecting MRD in DLBCL. The methylation of the p57KIP2 gene was analyzed in 63 cases of DLBCL by methylation-specific real-time quantitative PCR. Methylation of the p57KIP2 gene was detected in 53 (84.1%) of these 63 cases of DLBCL. We could detect one p57KIP2 gene-methylated cell among 10,000 unmethylated cells by the serial dilution experiment. This sensitivity is proved to be equivalent to that of detection of bcl2/IgH rearrangement by real-time quantitative PCR. This sensitivity could be converted to the detection of two methylated genomes per reaction. Using clinical material, the same results were confirmed. In this study, we established a convenient and universal method for detecting MRD in DLBCL. This technique is applicable for over 80% of patients with DLBCL. This could promote systemic MRD studies in the area of DLBCL.
Collapse
Affiliation(s)
- Kazumi Hagiwara
- Clinical Research Centre, National Hospital Organization, Nagoya Medical Center, Naka-ku, Nagoya, Japan
| | | | | | | | | | | | | |
Collapse
|
6
|
Yamazaki J, Baba K, Goto-Koshino Y, Setoguchi-Mukai A, Fujino Y, Ohno K, Tsujimoto H. Quantitative assessment of minimal residual disease (MRD) in canine lymphoma by using real-time polymerase chain reaction. Vet Immunol Immunopathol 2008; 126:321-31. [PMID: 18977540 DOI: 10.1016/j.vetimm.2008.09.004] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2008] [Revised: 08/25/2008] [Accepted: 09/12/2008] [Indexed: 11/25/2022]
Abstract
Lymphoma is the most common hematopoietic malignancy in dogs. Although a large proportion of dogs with lymphoma can achieve clinical remission by initial chemotherapy, most dogs die as a consequence of tumor relapse. We established a quantitative detection system for minimal residual disease (MRD) in canine lymphoma by using real-time polymerase chain reaction (PCR). A canine T-cell lymphoma-derived cell line, namely, UL-1, was used to examine the specificity and sensitivity of the MRD detecting system. Allele-specific oligonucleotide primers and probes were designed based on the sequence of T-cell receptor gamma chain (TCRgamma) gene fragment of UL-1 cells in conjunction with its downstream sequence, which were obtained from the dog genome database. The real-time PCR system for plasmid DNA containing the TCRgamma gene derived from UL-1 cells and the genomic DNA of UL-1 cells revealed that the system was accurate for 10-100,000 copies per reaction and its sensitivity was 1 cell per 10,000 cells. In order to monitor the kinetics of tumor cell number in canine lymphoma, we quantified the level of MRD in the peripheral blood of 7 dogs with lymphoma under chemotherapy. Since the lymphoma cells from the 7 patients were shown to be B-cell origin from the finding of clonal rearrangement of immunoglobulin heavy chain (IgH) gene, allele-specific oligonucleotide primers and probes were prepared based on the sequence of rearranged IgH gene in each case. The number of peripheral blood tumor cells measured by the real-time PCR was comparable to that estimated by conventional hematological examination in 2 cases of stage V lymphoma. MRD in the peripheral blood was detectable in all 7 cases, even in the complete remission (CR) phase. In the 7 lymphoma dogs, changes in the MRD levels of peripheral blood generally paralleled with the changes in the volumes of lymph nodes. Molecular CR, in which the MRD level was below the detection limit, was not observed in any of these 7 patients under chemotherapy. The MRD level detected by the real-time PCR method described here would be useful for investigating the kinetics of tumor cell growth and its regression in canine lymphoma patients.
Collapse
Affiliation(s)
- Jumpei Yamazaki
- Department of Veterinary Internal Medicine, Graduate School of Agricultural and Life Sciences, The University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan
| | | | | | | | | | | | | |
Collapse
|
7
|
Pennell N, Woods A, Reis M, Buckstein R, Spaner D, Imrie K, Hewitt K, Boudreau A, Seth A, Berinstein NL. Association of clinical status of follicular lymphoma patients after autologous stem cell transplant and quantitative assessment of lymphoma in blood and bone marrow as measured by SYBR Green I polymerase chain reaction. J Mol Diagn 2006; 8:40-50. [PMID: 16436633 PMCID: PMC1867565 DOI: 10.2353/jmoldx.2006.050050] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Molecular remission in the autograft and bone marrow after transplant are predictive of durable clinical remission in relapsed follicular lymphoma. Thus, a simple reliable method to quantify minimal residual disease (MRD) would improve prognostication in these patients. Fluorescent hybridization probes have been used in real-time quantitative polymerase chain reaction (RQ-PCR) to monitor MRD with a reproducible sensitivity of 0.01%; however, these techniques are expensive and require additional experiments to examine clonality. We describe a SYBR Green I detection method that is more universal, checks clonal identity, yields the same sensitivity for monitoring MRD, and is more economically attractive. Using this method to follow 14 follicular lymphoma patients treated with autologous stem cell transplantation, molecular markers were successfully defined for 12 patients. Median contamination of stem-cell grafts was 0.1% (range, 0 to 13%). Six patients with measurable graft contamination became PCR-negative in blood and bone marrow within 12 months after autologous stem cell transplantation. Three patients free of disease progression (median follow-up of 75 months) are in molecular remission. Increasing fractions of RQ-PCR-positive blood and bone marrow cells reliably predicted morphological and clinical relapse. In one case, both clinical relapse and spontaneous regression were reflected by changes in MRD levels. Thus, our RQ-PCR method reproducibly distinguishes different levels of MRD.
Collapse
Affiliation(s)
- Nancy Pennell
- Advanced Therapeutics Program, Toronto-Sunnybrook Regional Cancer Centre, Sunnybrook and Women's College Health Sciences Centre, 2075 Bayview Ave., Toronto, ON Canada M4N 3M5
| | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Ståhlberg A, Zoric N, Aman P, Kubista M. Quantitative real-time PCR for cancer detection: the lymphoma case. Expert Rev Mol Diagn 2005; 5:221-30. [PMID: 15833051 DOI: 10.1586/14737159.5.2.221] [Citation(s) in RCA: 51] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Advances in the biologic sciences and technology are providing molecular targets for diagnosis and treatment of cancer. Lymphoma is a group of cancers with diverse clinical courses. Gene profiling opens new possibilities to classify the disease into subtypes and guide a differentiated treatment. Real-time PCR is characterized by high sensitivity, excellent precision and large dynamic range, and has become the method of choice for quantitative gene expression measurements. For accurate gene expression profiling by real-time PCR, several parameters must be considered and carefully validated. These include the use of reference genes and compensation for PCR inhibition in data normalization. Quantification by real-time PCR may be performed as either absolute measurements using an external standard, or as relative measurements, comparing the expression of a reporter gene with that of a presumed constantly expressed reference gene. Sometimes it is possible to compare expression of reporter genes only, which improves the accuracy of prediction. The amount of biologic material required for real-time PCR analysis is much lower than that required for analysis by traditional methods due to the very high sensitivity of PCR. Fine-needle aspirates and even single cells contain enough material for accurate real-time PCR analysis.
Collapse
|
9
|
Uchiyama M, Maesawa C, Yashima-Abo A, Tarusawa M, Endo M, Sugawara W, Chida S, Onodera S, Tsukushi Y, Ishida Y, Tsuchiya S, Masuda T. Consensus JH gene probes with conjugated 3'-minor groove binder for monitoring minimal residual disease in acute lymphoblastic leukemia. J Mol Diagn 2005; 7:121-6. [PMID: 15681483 PMCID: PMC1867498 DOI: 10.1016/s1525-1578(10)60017-7] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
Abstract
Several approaches for the detection of minimal residual disease (MRD) in childhood acute lymphoblastic leukemia (ALL) have shown the importance of determining the level of MRD precisely. In the present study, we tested a new real-time quantitative polymerase chain reaction (RQ-PCR) strategy with minor groove binder (MGB) technology for immunoglobulin heavy chain gene rearrangements by positioning a MGB probe at the germline JH segments and one of the primers at the downstream introns in combination with an allele-specific oligonucleotide (ASO) primer complementary to the VH-DH or DH-JH junctional region. A MGB probe forms extremely stable duplexes with single-stranded DNA targets, allowing the use of shorter probes for hybridization-based assays. Therefore, it shows positional flexibility. We have designed two novel consensus MGB JH germline probes for analyzing all of the germline rearrangements registered in the V BASE database, and demonstrated that the MRD was detectable with the probes in 17 cases of childhood ALL. The actual copy number for the targets and dynamic changes before and after treatment were almost identical between the JH MGB probe and conventional non-MGB probes in each patient. MGB technology will undoubtedly contribute to MRD-PCR studies of childhood ALL.
Collapse
Affiliation(s)
- Michihiro Uchiyama
- Department of Pathology, Iwate Medical University School of Medicine, Uchimaru 19-1, 020-8505 Morioka, Japan
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Uchiyama M, Maesawa C, Yashima A, Tarusawa M, Satoh T, Ishida Y, Ito S, Murai K, Enomoto S, Utsugisawa T, Motoyoshi K, Masuda T. Development of consensus fluorogenically labeled probes of the immunoglobulin heavy-chain gene for detecting minimal residual disease in B-cell non-Hodgkin lymphomas. Cancer Sci 2003; 94:877-85. [PMID: 14556661 PMCID: PMC11160181 DOI: 10.1111/j.1349-7006.2003.tb01370.x] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2003] [Revised: 07/07/2003] [Accepted: 08/14/2003] [Indexed: 11/26/2022] Open
Abstract
We have examined 72 patients with B-cell non-Hodgkin lymphoma (B-NHL) in order to search for consensus sequences of the immunoglobulin heavy chain (IgH) gene, and developed consensus fluorogenically labeled probes for use in an allele-specific oligonucleotide (ASO) real-time quantitative polymerase chain reaction (RQ-PCR) assay of minimal residual disease (MRD). We detected a clonal IgH variable region (VH) sequence in 51 (70.8%) of the 72 B-NHLs, the most frequent VH gene usages being VH3 and VH4 (45/51, 88.2%). It was possible to design three consensus fluorogenic probes for the VH3 gene and one for the VH4 gene avoiding these hypermutations. Our sequencing results suggested that consensus fluorogenic probes would be best based on the 5'-side of the framework region 3 (FR3) because the frequency of somatic hypermutations was significantly lower in the regions on which the probes were based than in the remaining parts of FR3 (P < 0.05). Nineteen (54.3%) of 35 B-NHLs with the VH3 gene and 5 (50%) of 10 with the VH4 gene had sequences identical to at least one of these probes. We found that probes containing one base substitution were still applicable for a MRD study, whereas those containing two or more were not. Therefore, our four probes were applicable for 37 (82.2%) of the 45 patients with VH3 or VH4. This limited number of probes makes a large-scale study of MRD in B-NHL more feasible.
Collapse
MESH Headings
- Adult
- Aged
- Aged, 80 and over
- Base Sequence
- Biomarkers, Tumor/analysis
- Biomarkers, Tumor/genetics
- Consensus Sequence/genetics
- Female
- Fluorescence
- Humans
- Immunoglobulin Heavy Chains/chemistry
- Immunoglobulin Heavy Chains/genetics
- Lymphoma, B-Cell/diagnosis
- Lymphoma, B-Cell/genetics
- Lymphoma, B-Cell/pathology
- Male
- Middle Aged
- Molecular Sequence Data
- Mutation/genetics
- Neoplasm, Residual/diagnosis
- Neoplasm, Residual/genetics
- Neoplasm, Residual/pathology
- Polymerase Chain Reaction/methods
- Reference Standards
- Sequence Alignment
- Somatic Hypermutation, Immunoglobulin/genetics
Collapse
Affiliation(s)
- Michihiro Uchiyama
- Department of Pathology, Third Department of Internal Medicine, Iwate Medical University School of Medicine, Morioka 020-8505, Japan
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|